Immuneering Corp SEC filings IMRX

Immuneering Corp has 322 filings in SEC EDGAR's recent list, going back to Oct 4, 2019. Its latest annual report, Form 10-K, was filed on Mar 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.

Immuneering Corp SEC filings
Form Description Filed Period
424B5 Prospectus supplement Sep 25, 2025 —
FWP Free writing prospectus Sep 25, 2025 —
FWP Free writing prospectus Sep 24, 2025 —
424B5 Prospectus supplement Sep 24, 2025 —
424B3 Prospectus Sep 8, 2025 —
S-3 Shelf registration Sep 3, 2025 —
S-3 Shelf registration Aug 13, 2025 —
424B5 Prospectus supplement Jun 23, 2025 —
S-8 Employee stock plan registration May 5, 2025 —
424B5 Prospectus supplement Mar 20, 2025 —
424B5 Prospectus supplement Apr 19, 2023 —
424B5 Prospectus supplement Apr 18, 2023 —
S-3 Shelf registration Aug 10, 2022 —
S-8 Employee stock plan registration Aug 3, 2021 —
424B4 Prospectus Jul 30, 2021 —
S-1MEF Filing Jul 29, 2021 —
S-1/A Amended registration statement Jul 28, 2021 —
S-1/A Amended registration statement Jul 26, 2021 —
S-1 Registration statement Jul 9, 2021 —

Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
IMRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1790340

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.